Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improvements in disease ...

She also notes reassuring results from longer-term trials of fenebrutinib, another BTK inhibitor, in patients with relapsing MS. In all, as these therapies progress through trials, Dr Oh is ...

Next in line is Roche and Genentech’s fenebrutinib. The oral BTK candidate performed well in an open-label extension of the phase 2 FENopta study of patients with relapsing forms of MS. The vast ...

But three — tolebrutinib, fenebrutinib, and remibrutinib — are now in late-stage trials. The race is on as several drugmakers get closer to the finish line in developing the first Bruton tyrosine ...

Researchers expect the approach will show cognitive benefits via positive effects on a brain region called… A year of treatment with the experimental BTK inhibitor fenebrutinib was safe and ...

Another Trump term could spur Europe’s efforts to stand on its own, but it is far from clear its leaders will seize the moment this time. By Steven Erlanger Beijing is expecting more ...

President-elect Trump is projected to win the popular vote in the presidential election, a feat not achieved by a Republican candidate in 20 years. Current vote counts show Trump surpassing Vice ...